Split History
ETFs Holding APVO »    APVO Historical Stock Prices »
Video: What is a Stock Split?

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Aptevo Therapeutics is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. Co.'s lead clinical candidate, APVO436 is an ADAPTIR bispecific immunotherapeutic protein targeting CD123, a cell surface receptor highly expressed on several hematological malignancies and CD3, a component of the T-cell receptor. ALG.APV-527 is an investigational bispecific ADAPTIR candidate, partnered with Alligator Bioscience AB, featuring a mechanism of action designed to simultaneously target 4-1BB (CD137) and 5T4, a tumor antigen overexpressed in a number of different types of cancer. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate. According to our APVO split history records, Aptevo Therapeutics has had 1 split.
APVO split history picture
Aptevo Therapeutics (APVO) has 1 split in our APVO split history database. The split for APVO took place on March 27, 2020. This was a 1 for 14 reverse split, meaning for each 14 shares of APVO owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 71.4285714285714 share position following the split.

When a company such as Aptevo Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the APVO split history from start to finish, an original position size of 1000 shares would have turned into 71.4285714285714 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Aptevo Therapeutics shares, starting with a $10,000 purchase of APVO, presented on a split-history-adjusted basis factoring in the complete APVO split history. APVO split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 07/20/2016
End date: 09/27/2021
Start price/share: $112.00
End price/share: $15.98
Dividends collected/share: $0.00
Total return: -85.73%
Average Annual Total Return: -31.27%
Starting investment: $10,000.00
Ending investment: $1,427.25
Years: 5.19
Date Ratio
03/27/20201 for 14
APVO is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

ARA Split History
ARAV Split History
ARCT Split History
ARGS Split History
ARMP Split History
ARNA Split History
ARTC Split History
ARTL Split History
ARWR Split History
ASMB Split History

Also explore: APVO shares outstanding history

InMode Ltd. (INMD)
Sonim Technologies, Inc. (SONM)
AzurRx BioPharma, Inc. (AZRX)
Jaguar Health, Inc. (JAGX)
Microchip Technology Incorporated (MCHP)
ATIF Holdings Limited (ATIF)
Intuitive (ISRG)
Transportation Services, Inc. (PTSI)
Ashford Hospitality Trust, Inc. (AHT)
Staffing 360 Solutions, Inc. (STAF)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

APVO Insider Buying

APVO Split History | www.SplitHistory.com | Copyright © 2013 - 2021, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.